Cowen & Co. initiated coverage on Apollo Endosurgery with a new price target
$APEN
Industrial Specialties
Health Care
Cowen & Co. initiated coverage of Apollo Endosurgery with a rating of Outperform and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/4/2023 | $10.00 | Buy → Hold | Stifel |
| 11/30/2022 | $14.00 → $10.00 | Buy → Hold | Lake Street |
| 2/23/2022 | $12.00 → $10.00 | Buy | Stifel |
| 12/15/2021 | $13.00 | Outperform | Cowen & Co. |
| 12/9/2021 | $12.00 | Buy | Stifel |
| 9/9/2021 | $15.00 | Overweight | Stephens |
MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi
AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only op
SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13D/A - Apollo Endosurgery, Inc. (0001251769) (Subject)
SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)
15-12G - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)
K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w
Veteran Brings 30 Years of Multinational Healthcare Leadership ExperienceAUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products."Jeannette Bankes is a seasoned healthcare executive and board member known for applying her tremendous insight, experi
Veteran Leader Brings 25 Years of Global Medical Device ExperienceAUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022."At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss. We understand that developing products and procedures is only one component, and that facilitating patient access is a key element to successfully developing these markets," said Chas McKhann, president and CEO of A
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)
Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00
Lake Street downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00 from $14.00 previously
Stifel reiterated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $10.00 from $12.00 previously
MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th
MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric DevicesAUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.(3) These milestones come only months after Apollo received FDA
Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price
Upgrades For ONE Gas Inc (NYSE:OGS), Guggenheim upgraded the previous rating of Sell to Neutral. For the third quarter, ONE Gas had an EPS of $0.44, compared to year-ago quarter EPS of $0.38. The stock has a 52-week-high of $92.26 and a 52-week-low of $68.86. At the end of the last trading period, ONE Gas closed at $76.71. Guggenheim upgraded the previous rating for FirstEnergy Corp (NYSE:FE) from Neutral to Buy. In the third quarter, FirstEnergy showed an EPS of $0.79, compared to $0.82 from the year-ago quarter. The stock has a 52-week-high of $48.85 and a 52-week-low of $35.32. At the end of the last trading period, FirstEnergy closed at $42.20. For Ribbon Communications Inc (NASDAQ
Cowen & Co. analyst Joshua Jennings downgrades Apollo Endosurgery (NASDAQ:APEN) from Outperform to Market Perform and lowers the price target from $13 to $10.
Apollo Endosurgery's (NASDAQ:APEN) short percent of float has fallen 63.08% since its last report. The company recently reported that it has 425 thousand shares sold short, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.6 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short